Leveraging Illumina’s leading sequencing technology and informatics tools alongside Nvidia’s lea Illumina, Inc. (NASDAQ: ILMN) ("Illumina" or the "company") today announced unaudited ...

A collection of publications on comparison of high-throughput sequencing technologies.

Illumina, Inc. (NASDAQ: ILMN), a global leader in genomic sequencing and analysis, today announced it is collaborating with NVIDIA to advance technology platforms for the analysis and ...

Illumina and Regeneron are taking stakes in ... of Health’s All of Us million-person program and other massive DNA sequencing projects. The companies—supported by more than a dozen major ...

DNA synthesis by single polymerase molecules has been visualized at the speed of catalysis, heralding a new sequencing technology of unparalleled throughput. To enable parallel sequencing ...

Illumina, Inc. (NASDAQ:ILMN) is a healthcare company that offers sequencing and array-based solutions for genetic and genomic analysis. It is one of the stocks targeted by activist hedge funds ...

This important study reveals a role for IκBα in the regulation of embryonic stem cell pluripotency. The solid data in mouse embryonic stem cells include separation of function mutations in IκBα to ...

In vivo perturbations and single-cell RNA-seq reveal cell-type-specific STAT1-IFNg signaling in regulation of trained immunity in tissue-resident immune cells.

Reverse transcription of 100 ng RNA was performed using the SensiFAST cDNA Synthesis Kit (Meridian Bioscience, United States). TABLE 1. Primer pairs for qPCR. 2.6 RNA sequencing and analysis of ...